386 related articles for article (PubMed ID: 15606719)
1. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology.
Wolf G
Eur J Clin Invest; 2004 Dec; 34(12):785-96. PubMed ID: 15606719
[TBL] [Abstract][Full Text] [Related]
2. Diabetic nephropathy: where hemodynamics meets metabolism.
Forbes JM; Fukami K; Cooper ME
Exp Clin Endocrinol Diabetes; 2007 Feb; 115(2):69-84. PubMed ID: 17318765
[TBL] [Abstract][Full Text] [Related]
3. Reactive oxygen species amplify glucose signalling in renal cells cultured under high glucose and in diabetic kidney.
Ha H; Lee HB
Nephrology (Carlton); 2005 Oct; 10 Suppl():S7-10. PubMed ID: 16174288
[TBL] [Abstract][Full Text] [Related]
4. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
5. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy.
Cooper ME
Diabetologia; 2001 Nov; 44(11):1957-72. PubMed ID: 11719827
[TBL] [Abstract][Full Text] [Related]
6. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
7. Oxidative stress and advanced glycation in diabetic nephropathy.
Coughlan MT; Mibus AL; Forbes JM
Ann N Y Acad Sci; 2008 Apr; 1126():190-3. PubMed ID: 18448815
[TBL] [Abstract][Full Text] [Related]
8. Role of the JAK/STAT signaling pathway in diabetic nephropathy.
Marrero MB; Banes-Berceli AK; Stern DM; Eaton DC
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F762-8. PubMed ID: 16527921
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis of diabetic nephropathy.
Raptis AE; Viberti G
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S424-37. PubMed ID: 11460589
[TBL] [Abstract][Full Text] [Related]
10. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
Inagi R; Nangaku M; Miyata T
Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
[TBL] [Abstract][Full Text] [Related]
11. AGE, RAGE, and ROS in diabetic nephropathy.
Tan AL; Forbes JM; Cooper ME
Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
[TBL] [Abstract][Full Text] [Related]
12. From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy.
Miyata T; Yamamoto M; Izuhara Y
Ann N Y Acad Sci; 2005 Jun; 1043():740-9. PubMed ID: 16037301
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells.
Morcos M; Schlotterer A; Sayed AA; Kukudov G; Oikomonou D; Ibrahim Y; Pfisterer F; Schneider J; Bozorgmehr F; Rudofsky G; Schwenger V; Kientsch-Engels R; Hamann A; Zeier M; Dugi K; Yard B; Humpert PM; van der Woude F; Nawroth PP; Bierhaus A
Horm Metab Res; 2008 Nov; 40(11):752-9. PubMed ID: 18711692
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway.
Thallas-Bonke V; Thorpe SR; Coughlan MT; Fukami K; Yap FY; Sourris KC; Penfold SA; Bach LA; Cooper ME; Forbes JM
Diabetes; 2008 Feb; 57(2):460-9. PubMed ID: 17959934
[TBL] [Abstract][Full Text] [Related]
15. Kidney involvement and disease in patients with diabetes.
Chiarelli F; Trotta D; Verrotti A; Mohn A
Panminerva Med; 2003 Mar; 45(1):23-41. PubMed ID: 12682618
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
[TBL] [Abstract][Full Text] [Related]
17. Diabetic nephropathy: from mechanisms to rational therapies.
Giunti S; Barit D; Cooper ME
Minerva Med; 2006 Jun; 97(3):241-62. PubMed ID: 16855519
[TBL] [Abstract][Full Text] [Related]
18. Different roles for TGF-beta and VEGF in the pathogenesis of the cardinal features of diabetic nephropathy.
Ziyadeh FN
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S38-41. PubMed ID: 18842317
[TBL] [Abstract][Full Text] [Related]
19. Transcription factors in the pathogenesis of diabetic nephropathy.
Sanchez AP; Sharma K
Expert Rev Mol Med; 2009 Apr; 11():e13. PubMed ID: 19397838
[TBL] [Abstract][Full Text] [Related]
20. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy.
Ha H; Hwang IA; Park JH; Lee HB
Diabetes Res Clin Pract; 2008 Nov; 82 Suppl 1():S42-5. PubMed ID: 18845352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
